US Medical Affairs Strategy Hematology Intern
Genmab
Summary
The US Medical Affairs Strategy Intern will join the US Medical Affairs Hematology team, supporting medical strategy and scientific initiatives in diffuse large B-cell lymphoma. Working with a dedicated mentor, the intern will contribute to congress preparation, scientific education, and medical insight analysis while gaining exposure to Field Medical, Training, and Medical Information.
Job description
Job Overview
The US Medical Affairs Strategy Intern will join the US Medical Affairs Hematology team, supporting medical strategy and scientific initiatives in diffuse large B-cell lymphoma. Working with a dedicated mentor, the intern will contribute to congress preparation, scientific education, and medical insight analysis while gaining exposure to Field Medical, Training, and Medical Information.
What You'll Do
- Support summer medical congress preparation and follow-up by reviewing abstracts, identifying relevant presentations, and developing summaries of emerging clinical data and their implications for US medical strategy.
- Lead an internal journal club under mentor guidance: select a relevant publication, critically evaluate its design and findings, develop a presentation, and facilitate discussion of clinical and strategic implications.
- Analyze field medical insights and team reports to identify recurring themes, unmet needs, and barriers to care; prepare a summary with recommendations for the Strategy team.
- Under mentor guidance, contribute to scientific education and Field Medical resources, such as development of Field Medical training material and review of Field Medical resources. Design and help deliver role-specific onboarding, hands-on workshops, and office hours; connect tool demonstrations to real business tasks and help colleagues apply what they learn.
Required Qualifications, Capabilities And Skills
- Currently pursuing an advanced degree in pharmacy, medicine, life sciences, or a related health discipline (e.g., PharmD, PhD, MD, or master's degree).
- Foundational understanding of medical terminology, clinical trial design, and basic statistics through coursework or research experience.
- Ability to search scientific literature using resources such as PubMed and critically summarize study objectives, methods, results, and limitations.
- Proficiency in Microsoft PowerPoint, Excel, and Word, including creating presentations, organizing data, and preparing documents; ability to manage project deadlines and incorporate feedback.
Preferred Qualifications, Capabilities And Skills
Coursework, research, or clinical experience in oncology, hematology, immunology, or cancer therapeutics; familiarity with lymphoma is a plus.
Requirements
- Currently pursuing an advanced degree in pharmacy, medicine, life sciences, or a related health discipline (e.g., PharmD, PhD, MD, or master's degree)
- Foundational understanding of medical terminology, clinical trial design, and basic statistics through coursework or research experience
- Ability to search scientific literature using resources such as PubMed and critically summarize study objectives, methods, results, and limitations
- Proficiency in Microsoft PowerPoint, Excel, and Word, including creating presentations, organizing data, and preparing documents
- Ability to manage project deadlines and incorporate feedback
- Coursework, research, or clinical experience in oncology, hematology, immunology, or cancer therapeutics (preferred)
- Familiarity with lymphoma (preferred)
Company overview
Genmab is a leading international biotechnology company headquartered in Copenhagen, Denmark, specializing in the development and commercialization of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has established itself as a pioneer in antibody technology with its proprietary DuoBody, HexaBody, and DuoHexaBody platforms. Genmab's innovative approach focuses on creating next-generation antibody-based therapies that target specific cancer cells while minimizing damage to healthy tissues. The company has several marketed products including DARZALEX (daratumumab) for multiple myeloma, which has become a cornerstone treatment in hematological malignancies. Genmab's pipeline includes numerous clinical-stage candidates targeting various cancers, leveraging its expertise in antibody engineering to develop novel immunotherapies. The company collaborates with major pharmaceutical partners worldwide and maintains a strong commitment to advancing cancer treatment through cutting-edge science and patient-focused innovation.